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Abstract
Increased expression of Notch signaling pathway components is observed in Kaposi sarcoma (KS), but the mechanism
underlying the manipulation of the canonical Notch pathway by the causative agent of KS, Kaposi sarcoma herpesvirus
(KSHV), has not been fully elucidated. Here, we describe the mechanism through which KSHV directly modulates the
expression of the Notch ligands JAG1 and DLL4 in lymphatic endothelial cells. Expression of KSHV-encoded vFLIP induces
JAG1 through an NFkB-dependent mechanism, while vGPCR upregulates DLL4 through a mechanism dependent on ERK.
Both vFLIP and vGPCR instigate functional Notch signalling through NOTCH4. Gene expression profiling showed that JAG1-
or DLL4-stimulated signaling results in the suppression of genes associated with the cell cycle in adjacent lymphatic
endothelial cells, indicating a role for Notch signaling in inducing cellular quiescence in these cells. Upregulation of JAG1
and DLL4 by KSHV could therefore alter the expression of cell cycle components in neighbouring uninfected cells during
latent and lytic phases of viral infection, influencing cellular quiescence and plasticity. In addition, differences in signaling
potency between these ligands suggest a possible complementary role for JAG1 and DLL4 in the context of KS.
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Introduction
The Notch pathway is an evolutionarily conserved signaling
mechanism that transduces signals between adjacent cells and has
an established role in cell fate determination during development,
tissue homeostasis and stem cell maintenance [1,2]. The Notch
receptors (NOTCH1–NOTCH4) and ligands (JAG1, JAG2,
DLL1, DLL3, and DLL4) are membrane-bound proteins that
associate through their extracellular domains. Receptor-ligand
interaction stimulates sequential proteolytic cleavage events at the
receptor that release the intracellular domain (ICD) for translo-
cation to the nucleus of the receiving cell. The ICD contributes to
a ternary complex, involving the transcription factor CSL (CBF-1,
Su(H), Lag-1), and upregulates transcription of target genes,
primarily members of the HES and HEY families of transcrip-
tional repressors [3]. The outcome of Notch signaling is cell-type
dependent [4–6] and this pathway has essential roles during
physiological and pathological angiogenesis [7].
NOTCH1, NOTCH4, JAG1 and DLL4 are expressed on
vascular endothelium. New vessel ‘‘tip’’ cells form the guiding cells
of endothelial sprouts and Notch signaling is essential for the
specification of these cells. Ligand expression confers the tip
phenotype and suppresses it in neighbouring receiving cells under
physiological (DLL4) and pathological (JAG1) conditions [8–11].
Distinct spatial expression of DLL4 and JAG1 in normal
developing vasculature suggests that ligand-specific outcomes of
Notch signaling are required for normal development [12,13].
Cells adjacent to the tip cells form the stalk of the vessel and are
subject to quiescent growth arrest. Notch signaling is also
implicated in the maintenance of a reversible, quiescent state in
stem cell progenitors [14,15] and is associated with growth arrest
in a number of systems through manipulation of cell cycle
components including minichromosome maintenance (MCM)
proteins and cyclin dependent kinase inhibitors (CDKIs) [16–19].
Kaposi sarcoma herpesvirus (KSHV, also called HHV-8) is an
oncogenic c-herpesvirus that is the etiological agent of Kaposi
sarcoma (KS), a neoplasm of lymphatic endothelial cells (LEC)
[20]. KSHV is also associated with lymphoproliferations such as
multicentric Castleman’s disease (MCD) [21]. KS is an angiopro-
liferative disease composed of sheets of spindle cells (the KS
tumour cells), an inflammatory infiltrate and abnormal slit-like
blood vessels. All KS spindle cells are infected by KSHV [22].
During the establishment of host infection, two phases of viral
infection exist: latent and lytic. The majority of spindle cells are
latently infected and express a limited number of viral genes
including the viral FLICE inhibitory protein (vFLIP); productive
(lytic) viral infection is associated with expression of an increased
number of viral genes including the multifunctional viral G
protein-coupled receptor (vGPCR) [23].
KS lesions express elevated levels of Notch signaling compo-
nents and experimental lesions appear sensitive to inhibition of this
pathway [24,25]. The KSHV ORF50 gene product, RTA, has
been shown to induce expression of HEY1 during lytic
reactivation of the virus [26–28], but a mechanism through which
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proteins, specifically during latency, has not been described. Here
we show that KSHV specifically increases the expression of the
Notch ligands JAG1 and DLL4 and the receptor NOTCH4 in
LEC. The increase in JAG1 and DLL4 is attributable to the viral
genes vFLIP and vGPCR, through mechanisms dependent on the
NFkB and ERK pathways respectively. We demonstrate that
JAG1 and DLL4 stimulate Notch signaling in adjacent LEC and
alter the expression of cell cycle-associated genes. The suppression
of a number of these genes is observed in LEC adjacent to vFLIP-
and vGPCR-expressing cells and during KSHV infection of LEC;
the effect of Notch on cell cycle components could offer a growth
advantage to infected cells during the pathogenesis of KS. These
data also suggest that DLL4 and JAG1 may have a similar role
during sprouting lymphangiogenesis as has been observed in blood
vessel endothelial cells during angiogenesis, where Notch induces
quiescence in developing vascular sprouts.
Results
KSHV infection of LEC increases the expression of specific
components of the Notch signaling pathway and
activates canonical Notch signaling
KS has been shown to be sensitive to c-secretase inhibition in
murine models [24,25]. We have previously described the
transcriptional signature of KSHV-infected LEC (KLEC) [29]
and therefore analysed these data with respect to the expression of
the core components of the Notch signaling pathway including
HES and HEY Notch targets (Figure 1A). This analysis indicated
significant changes in the expression of specific members of the
pathway at the mRNA level following KSHV infection (false
discovery rate threshold q#0.005; Figure 1A). Significant increase
in expression was restricted to three ligands (DLL4, JAG1 and
DLL3), the HES1 and HEY1 targets and the NOTCH4 receptor.
The expression of all other Notch receptors was significantly
decreased along with the remaining Notch target genes analysed.
The expression of an additional Notch target, HES5, and the
Notch ligand DLL1 were not significantly altered.
The established role of Notch signaling through these
components during angiogenesis prompted us to consider these
data with respect to a list of 79 angiogenesis-associated genes that
Figure 1. KSHV alters the expression of core Notch components
in LEC and activates canonical Notch signalling. (A) Heatmap
representing the most significant relative changes in gene expression of
Notch pathway components in LEC following KSHV infection (q value #
0.05). Gene names in bold indicate genes significantly altered in the
context of a list of 79 angiogenic genes. Genes are ordered by magnitude
of fold change. Original GEM data from [29]. Red and yellow denote low
and high expressionrespectively. (B) Graphsof the average fold change in
the indicated mRNA in LEC and KLEC from at least three independent
experiments. **, P,0.01, ***,P,0.001,withrespect toLEC.Representative
corresponding protein levels shown below each graph. (C) HEY1 mRNA
levels in LEC and KLEC transfected with non-silencing siRNA (2)o rs i R N A
targeting NOTCH1 (N1) or NOTCH4 (N4). Columns are the average fold
change from three independent experiments. **, P,0.01, with respect to
LEC or KLEC transfected with a non-silencing control.
doi:10.1371/journal.ppat.1000616.g001
Author Summary
Kaposi sarcoma herpesvirus (KSHV) is a tumour virus
associated with Kaposi sarcoma (KS). Most KS tumor cells
are latently infected with the virus, while a small number
are lytically infected and produce KSHV. The Notch
signaling pathway is highly conserved and important in
development and disease. Classical activation of this
pathway occurs through direct interaction between
ligands and receptors bound to the surface of adjacent
cells and influences gene expression in cells receiving the
signal. KS tumour cells express Notch pathway compo-
nents and are sensitive to inhibition of Notch signaling,
suggesting this pathway may be important in the
development of KS; however, no mechanism behind the
classical activation of Notch by KSHV has been established.
We describe the molecular mechanisms through which
KSHV hijacks the Notch signaling pathway by directly
increasing the expression of two Notch ligands (JAG1 and
DLL4) through two KSHV genes expressed during latent
and lytic infection, respectively. We show the effect of
JAG1- and DLL4-stimulated signaling on gene expression
in adjacent cells and show that both ligands affect cell
cycle-associated genes and may co-operate to permit
functional signaling in the context of both latent and lytic
infection.
KSHV Regulates DLL4 and JAG1 Expression
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DLL4, the NOTCH4 receptor and the Notch target, HEY1 were
among the most highly upregulated (in bold in Figure 1A). The
gene expression microarray (GEM) data for these components
were validated at the mRNA and protein levels (Figure 1B).
Western blotting for NOTCH4 indicated a band at ,70 kDa, the
predicted size of the NOTCH4 intracellular domain (N4-ICD); no
band corresponding to the full-length protein was observed. This
indicated that the increased NOTCH4 could be involved in active
Notch signaling in LEC.
Notch pathway activation has been described in cells from
plaque stage KS lesions [25], suggesting that this pathway has a
role in latent infection. NOTCH4 was the most significantly
upregulated receptor in the context of primary KSHV infection.
We therefore investigated whether the upregulation of HEY1 in
KLEC was dependent on the expression of this receptor
(Figure 1C). LEC were transfected with siRNA against the
NOTCH4 receptor, and NOTCH1 as a control, to achieve knock-
down of the corresponding mRNA of 50% and 40% respectively
(Figure S1). KSHV induced a reproducible five-fold increase in
HEY1 expression. This increase was unaffected by the knock-
down of NOTCH1, but was reduced by approximately 60% in the
presence of NOTCH4 siRNA (Figure 1C). These data suggest
KSHV increases HEY1 levels in LEC through a mechanism
dependent on the NOTCH4 receptor. They also indicate that
there is no functional redundancy between NOTCH1 and
NOTCH4 in this system as the maintained expression of
NOTCH1 was not sufficient to rescue HEY1 levels in the
presence of NOTCH4 knock-down. HEY1 levels were not
reduced to baseline levels in the presence of NOTCH4 siRNA;
this may be attributed to a receptor-independent induction of
HEY1 as a consequence of the expression of low levels of KSHV
ORF50 during primary infection [28,31], or due to incomplete
knock-down of NOTCH4.
vFLIP increases levels of JAG1 through an NFkB-
dependent mechanism and instigates Notch signaling
through NOTCH4
JAG1 is an NFkB-responsive gene [32] and is induced in
endothelial cells through an NFkB-dependent mechanism [8,11].
Treatment of LEC and KLEC with a chemical inhibitor of the
NFkB pathway, BAY11-7082 [33], significantly reduced the basal
and KSHV-induced expression of JAG1 in LEC (Figure 2A).
These data suggest that the NFkB pathway is important in the
maintenance and induction of JAG1 levels. JAG1 expression is not
induced in LEC following exposure to KLEC-conditioned media
(Figure S2A), suggesting that the KSHV-induced increase in JAG1
in LEC does not occur via a paracrine mechanism.
Increased expression of JAG1has been suggested to correlate with
later-stage KS, specifically plaque and nodular lesions where latent
KSHV infection predominates [25,34]. The restricted number of
viral genes expressed during latency includes vFLIP, a potent
activator of the NFkB pathway [35]. To examine whether vFLIP
can induce JAG1 expression, LEC were infected with lentivirus
expressing vFLIP. Increased expression of MHC-I in vFLIP-LEC
was used as a control for vFLIP functional expression ([29], data not
shown). Compared to control cells infected with pSIN lentivirus,
levelsofJAG1mRNAwere increased byapproximatelythree-foldin
vFLIP-expressing LEC; this induction was abrogated by BAY11-
7082 (Figure 2B). vFLIP increased JAG1 protein expression in LEC
as measured by western blotting and increased JAG1 was also
observed in the spindle-shaped cells characteristic of vFLIP infection
(Figure 2C). LEC infected with lentivirus expressing the lytic viral
gene K15-P, another inducer of the NFkB pathway [36] did not
induce JAG1 expression inLEC (data not shown). Collectively, these
data suggest that JAG1 expression is induced primarily by vFLIP
through an NFkB-dependent mechanism.
We next investigated whether vFLIP could induce Notch
signaling in LEC by measuring levels of the Notch target, HEY1.
Expression of vFLIP induced a four-fold increase in HEY mRNA
that was abrogated in cells treated with a c-secretase inhibitor
(GSI-I) (Figure 2D), suggesting this induction of HEY1 may
depend on canonical Notch signaling. The NOTCH4 receptor
expression appeared to be most significant in the context of
primary KSHV infection of LEC (Figure 1C). We therefore
investigated if the increase in HEY1 by vFLIP was dependent
on NOTCH4. vFLIP-expressing LEC had elevated levels of
NOTCH4-ICD, detectable by western blot (Figure 2E), and
siRNA knockdown of NOTCH4 (Figure S2B) reduced HEY1
mRNA to near basal levels (Figure 2E). These data suggest that
vFLIP induces HEY1 expression by way of NOTCH4. Using the
co-culture assay described in Figure 2F, we investigated if vFLIP
could induce Notch signaling between adjacent cells. HEY1
expression in the receiving cells was assessed by qRT-PCR and
was found to be significantly increased in cells exposed to vFLIP or
JAG1 donors (Figure 2G). No significant change in another Notch
target gene, HES1, was observed. These data suggest that vFLIP
can induce HEY1 expression in adjacent cells, through a
mechanism involving JAG1 and NOTCH4.
vGPCR increases levels of DLL4 through an ERK-
dependent mechanism
DLL4 expression in LEC is not significantly affected by vFLIP
(Figure S3A) suggesting an alternative mechanism for its induction
in KLEC. The Notch pathway is required for arterial specification
[37–39], and DLL4 expression is essential for arterial patterning
and lymphatic sprouting [40–42]. Activation of extracellular-signal
regulated kinase (ERK) is also required for the arterial commit-
ment of angioblasts [43,44] suggesting a functional link between
these two pathways. siRNA knock-down of ERK1 and ERK2
(Figure S3B) significantly reduced KSHV-induced DLL4 expres-
sion in LEC (Figure 3A) suggesting a role for this pathway in the
upregulation of DLL4 during viral infection. The KSHV vGPCR
is a potent activator of ERK signaling [45,46]; levels of DLL4 were
therefore investigated in LEC infected with lentivirus expressing
vGPCR. Compared to cells expressing pSIN, levels of DLL4
mRNA were increased approximately three-fold in vGPCR-LEC.
This increase was also observed at the protein level (Figure 3B).
vGPCR activates multiple signaling cascades [47]. To confirm
that the induction of DLL4 by vGPCR is dependent on the ERK
pathway, pSIN- and vGPCR-expressing LEC were treated with
pharmacological inhibitors of the NFkB, ERK and PI3K pathways
(Figure 3C). DLL4 expression was significantly reduced following
ERK pathway inhibition only and was unaffected by the BAY11-
7082 compound. This agrees with our observation that vFLIP fails
to induce DLL4 expression (Figure S3A). Inhibition of the PI3K
pathway did not affect the vGPCR-induced increase in DLL4;
however, increased basal DLL4 expression was observed
(Figure 3C). This may reflect an antagonistic role for PI3K
signaling in DLL4 levels in LEC, as has been observed during blood
vessel specification [43,44]. Other KSHV genes can also activate
ERK signaling. To investigate the specificity of DLL4 induction by
vGPCR, LEC were infected with lentivirus expressing K15-P or
Kaposin A as examples of genes known to activate ERK signaling
during lytic and latent infection respectively [36,48]. Neither of
these viral genes increased DLL4 levels (Figure S3C). Collectively,
these data suggest that vGPCR induces DLL4 expression through
an ERK pathway-dependent mechanism.
KSHV Regulates DLL4 and JAG1 Expression
PLoS Pathogens | www.plospathogens.org 3 October 2009 | Volume 5 | Issue 10 | e1000616Figure 2. vFLIP induces JAG1 expression in LEC through the NFkB pathway. (A) JAG1 mRNA levels in LEC and KLEC treated with BAY11-
7082 (BAY11) or the equivalent volume of DMSO. Columns are the average fold change from two independent experiments. **, P,0.01, ***, P,0.001,
with respect to the corresponding DMSO control. (B) Mean fold change in JAG1 mRNA in pSIN- or vFLIP-expressing LEC treated with BAY11-7082
(BAY11) or the equivalent volume of DMSO. Columns represent the mean fold change from at least 3 independent experiments. ***, P,0.01 with
respect to DMSO-treated pSIN-infected or vFLIP-infected LEC, indicated by the horizontal bars. (C) Representative western blot and
immunoflourescence image showing increased JAG1 protein in pSIN- or vFLIP-LEC. Green, JAG1, blue, DAPI. (D) Mean fold change in HEY1 mRNA
in vFLIP-LEC in the presence of c-secretase inhibitor (GSI-I) or the equivalent volume of DMSO. Columns are the mean fold change from two
independent experiments. ***, P,0.001, with respect to DMSO-treated pSIN- or vFLIP-infected LEC, indicated by the horizontal bars. (E) Left panel,
HEY1 mRNA in LEC transfected with non-silencing siRNA or siRNA targeting NOTCH4 (N4). Columns are the average fold change from three
independent experiments. **, P,0.01, ***, P,0.001, with respect to pSIN or vFLIP-LEC transfected with a non-silencing control, indicated by the
horizontal bars. Right panel, levels of NOTCH4-ICD protein in pSIN- and vFLIP-LEC. (F) Schematic representation of the co-culture assay. Ligand-
expressing donor cells were generated by infection with the appropriate lentivirus and mixed with receiving cells, stained green, as described
according to Materials and Methods. (G) HEY1 mRNA levels in receiving cells co-cultured with LEC over-expressing JAG1 or infected with vFLIP.
Columns are the average fold change from three independent experiments. **, P,0.01, with respect to cells co-cultured with pSIN-infected LEC.
doi:10.1371/journal.ppat.1000616.g002
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PLoS Pathogens | www.plospathogens.org 4 October 2009 | Volume 5 | Issue 10 | e1000616Figure 3. vGPCR induces DLL4 expression in LEC through an ERK-dependent mechanism. (A) DLL4 mRNA levels in LEC and KLEC in the
presence of non-silencing (2) or ERK1/2 (+) siRNA. Columns are the average fold change from two independent experiments. ***, P,0.001, with
respect to the corresponding non-silencing control. P=0.056 between LEC samples. (B) (Left panel) DLL4 mRNA in pSIN- or vGPCR-LEC. Columns are
the average fold change from at least three independent experiments. **, P,0.01 with respect to pSIN-infected LEC. (Right panel) DLL4 protein in
cells infected with pSIN- or vGPCR-expressing lentivirus. (C) DLL4 mRNA levels in pSIN- or vGPCR-LEC treated with the inhibitors BAY11-7082 (BAY11),
UO126, LY294002 or the equivalent volume of DMSO. Columns are the average fold change from two independent experiments. ***, P,0.001,
**, P,0.01 with respect to the corresponding DMSO-treated control. (D) DLL4 (light grey bars) and JAG1 (dark grey bars) mRNA levels in BCBL1 cells
expressing pSIN or ORF50. Columns, average fold change from three independent experiments. ***, P,0.001, with respect to pSIN-expressing
control. (E) Mean fold change in HEY1 (black bars) and HES1 (grey bars) mRNA in vGPCR-LEC treated with 5 mM GSI-I or the equivalent volume of
DMSO. Columns are the mean fold change from two independent experiments. **, P,0.01, with respect to DMSO-treated pSIN- or vGPCR-LEC,
indicated by the horizontal bars. (F) (Left panel) HEY1 mRNA levels in vGPCR-infected LEC, transfected with non-silencing siRNA or siRNA targeting
NOTCH4 (N4). Columns, average fold change from three independent experiments. **, P,0.01, ***, P,0.001, with respect to pSIN- or vGPCR-LEC
transfected with a non-silencing control, as indicated by horizontal bars. (Right panel) western blot showing elevated levels of NOTCH4-ICD. (G)
Expression of HEY1 (black bars) and HES1 (grey bars) mRNA in adjacent cells co-cultured with LEC over-expressing DLL4 or infected with vGPCR.
Columns are the average fold change from three independent experiments. *, P,0.05, **, P,0.01 and ***, P,0.001, with respect to cells co-cultured
with pSIN-LEC.
doi:10.1371/journal.ppat.1000616.g003
KSHV Regulates DLL4 and JAG1 Expression
PLoS Pathogens | www.plospathogens.org 5 October 2009 | Volume 5 | Issue 10 | e1000616VEGF can induce DLL4 expression in blood vessel endothelial
cells during physiological and pathological angiogenesis [49–53]
and vGPCR can stimulate VEGF production [54,55]. We
observed a two-fold increase in the expression of VEGF in
vGPCR-expressing LEC (Figure S3D); however, LEC grown in
vGPCR-conditioned media in the presence or absence of a
VEGFR inhibitor, did not show increased DLL4 expression
(Figure S3E). LEC did not demonstrate increased levels of DLL4
in response to VEGF at concentrations previously reported to
induce DLL4 expression [49,50,53] (Figure S3F). These data
suggest that the induction of DLL4 in LEC by vGPCR does not
occur through a paracrine mechanism involving VEGF and that
direct activation of ERK by vGPCR is sufficient to elevate levels of
DLL4 in these cells.
JAG1 expression can also be affected by ERK signaling [56], so
we investigated levels of JAG1 in vGPCR LEC. We observed
reduced levels of JAG1 in these cells (Figure S3G) suggesting that
vGPCR preferentially induces DLL4 and this may indicate a role
for DLL4 during KSHV lytic infection. To begin to investigate
this hypothesis, we expressed KSHV ORF50 in the BCBL1 PEL
cell line, which is sufficient to reactivate KSHV from latency [57].
The induction of lytic infection was confirmed by measuring
significantly increased expression of ORF50 and the late-lytic gene
ORF26. An accompanying 2.5-fold increase in vGPCR expression
was also observed (Figure S3H). Compared to control, ORF50
cells expressed significantly more DLL4 (1.8-fold, Figure 3D),
while levels of JAG1 remained unchanged. The outcome of Notch
signaling, including signaling strength, can be influenced by the
type of ligand expressed [58,59]. These data suggest that DLL4
expression may have a role during the lytic phase of the KSHV
cycle and complements signaling established by JAG1 during
latency.
DLL4 has been shown to elevate levels of both HES1 and
HEY1 in HUVEC [53,60], so we examined levels of these Notch
targets in vGPCR-LEC. Levels of HEY1 and HES1 mRNA were
increased about 2.5-fold in vGPCR-LEC and these increases were
abrogated following GSI-I treatment (Figure 3E). These data
suggest the Notch pathway is involved in the upregulation of
HES1 and HEY1 in response to vGPCR. siRNA-mediated
silencing of NOTCH4 (Figure S3I) significantly reduced HEY1
expression (Figure 3F), suggesting that vGPCR induces HEY1
through a canonical Notch signaling mechanism involving
NOTCH4 and emphasising the importance of this receptor
during KSHV infection. In agreement, vGPCR-expressing cells
have elevated levels of NOTCH4-ICD protein indicating
activation of this receptor (Figure 3F). HES1 expression was not
significantly reduced in the presence of NOTCH4 siRNA alone
(data not shown) but combined knock-down of NOTCH1 and
NOTCH4 significantly reduced HES1 levels and increased levels
of NOTCH1-ICD protein were observed in vGPCR-LEC (Figure
S3J). These suggest that induction of HES1 in vGPCR-expressing
LEC can occur through either NOTCH1 or NOTCH4,
indicating a specific role for NOTCH1 in DLL4-stimulated
signaling. Utilising our co-culture assay, we examined levels of
HES1 and HEY1 in cells adjacent to vGPCR or DLL4-expressing
donors. Under both these conditions, HES1 and HEY1 were
significantly increased (Figure 3G). These data indicate that
DLL4-stimulated Notch signaling can induce HES1 and HEY1 in
adjacent LEC and that this signaling is mimicked by vGPCR.
Notch signaling suppresses the expression of cell cycle
components in LEC
To investigate the role of DLL4- and JAG1-stimulated Notch
signaling in LEC, we performed gene expression microarray
(GEM) analysis on LEC co-cultured with DLL4- or JAG1-
expressing donors. The ligands were expressed to equivalent levels
in donor cells as analysed by western blot (Figure S4A). Stringent
selection (false discovery rate threshold q,0.05) generated a list of
the most significantly altered genes in the receiving cells as a
consequence of exposure to DLL4 or JAG1 (Table S1). We
confirmed the GEM data by validating members of this genelist by
qRT-PCR and observed increased expression of CD38 and
LYVE1, and decreased levels of NRP1, a known target of DLL4-
induced Notch signaling [60,61] (Figure S4B). We confirmed that
receiving cells upregulated Notch target genes in response to both
DLL4 and JAG1 compared to pSIN (Figure 4A). In agreement
with our previous data, DLL4 stimulated significant increase in
HEY1 and HES1 expression (approximately four-fold) whereas
JAG1 resulted in significant increase in HEY1 only (nearly three-
fold). These data indicate that DLL4 induced a more pronounced
change in Notch target gene expression, which is reflected in the
heatmaps from two HEY1 probes (Figure 4A). Similarly, when the
165 genes most significantly altered in response to DLL4 are
considered, (Figure S4C and Table S2); these changes are
mimicked in JAG1-stimulated cells but are less pronounced.
Less stringent selection using an unadjusted P threshold of 0.005
generated a larger data set of significantly regulated genes on
which gene ontology analysis was performed using GENECODIS
[62]. This analysis indicated that, amongst genes suppressed in
cells stimulated by both DLL4 and JAG1, cell cycle, cell division
and mitotic pathways were enriched. Specifically, cyclins (CCN),
cyclin-dependent kinase 1 (CDK1), mitotic arrest deficient-like 1
(MAD2L1) and MCM proteins, were indicated by the GEM data
as significantly down-regulated in both JAG1- and DLL4-receiving
cells (Figure 4B). The CKI p57
Kip2 (CDKN1C) was uniquely
upregulated by JAG1 (Figure 4B); no significant change in other
CKIs, such as p21
Cip1, p27
Kip1 or members of the INK4 family,
was observed, despite associations with Notch signaling in other
systems [16,63]. Significant down-regulation of CCNA1, CCNB1,
CCNE1, CCNE2 and CCNF; CDC2 (CDK1), MCM4, MCM10
and MAD2L1 was confirmed by qRT-PCR for both JAG1- and
DLL4-receiving cells (Figure 4C, left panel). The JAG1-dependent
increase in p57 predicted by GEM analysis was also confirmed
(Figure 4C, right panel). MAD2L1 is part of a six-gene expression
signature, including the upregulation of HES1, characteristic of
quiescence triggered by a variety of arrest signals [64]. The co-
ordinated expression of p57
Kip2 and HES1 has also been
associated with quiescence reversibility [14,15]. Collectively, these
observations suggest a role for DLL4 and JAG1 in manipulating
the cell cycle in adjacent LEC.
To investigate whether the changes observed in Notch ligand-
stimulated cells were recapitulated by vGPCR or vFLIP, we
measured the expression of these genes in receiving cells co-
cultured with vGPCR- or vFLIP-expressing LEC (Figure 4D). We
confirmed significant reduction in CCNA1, CCNB1, CCNE1,
CCNE2, MAD2L1 and CDK1 in response to vGPCR and vFLIP
co-culture respectively. CCNA1 expression was reduced in all four
co-culture conditions. To investigate a role for the suppression of
these genes in the context of KSHV infection, we measured their
expression in KLEC and observed that these genes were
significantly down-regulated (Figure 4E), with the exception of
the E-type cyclins (not shown). Significantly reduced expression of
CCNF, MCM4 and MCM10 was also observed in KLEC (Figure
S4D). These data suggest that cell cycle components are targets of
Notch signaling in LEC and are suppressed in cells adjacent to
those expressing KSHV viral genes, suggesting that Notch
signaling may influence the cell cycle in cells adjacent to those
infected by KSHV.
KSHV Regulates DLL4 and JAG1 Expression
PLoS Pathogens | www.plospathogens.org 6 October 2009 | Volume 5 | Issue 10 | e1000616Figure 4. Notch signaling down-regulates cell cycle components in adjacent LEC. (A) (Top panel) Mean fold change in HEY1 (black bars)
and HES1 (grey bars) mRNA in receiving LEC co-cultured with either DLL4- or JAG1-overexpressing donor cells. Columns are the mean fold change
from three independent co-culture experiments. cDNA from these experiments was hybridised to HG-U133 Plus 2.0 Array (Affymetrix) ***, P,0.001,
and **, P,0.01, with respect to receiving cells co-cultured with pSIN-LEC. (Bottom panel) Heatmap based on gene expression array profiling
representing HEY1 expression in receiving cells co-cultured with pSIN, DLL4 or JAG1 in triplicate. Rows correspond to two HEY1 probe sets; red and
yellow denote low and high expression respectively, P,0.01. (B) (Top panel) Heatmap illustrating the relative changes in expression of cell cycle
genes significantly altered in LEC co-cultured with DLL4 and JAG1 compared to pSIN. (Bottom panel) Heatmap illustrating the specific upregulation of
CDKN1C (p57
Kip2) in JAG1-stimulated LEC according to six probe sets P,0.01. (C) (Top panel) mRNA levels of cell cycle components altered by DLL4
and JAG1-induced Notch signaling in receiving LEC. Columns are the mean fold change from three independent co-culture experiments, values are
normalised to LEC co-cultured with pSIN. ***, P,0.001, **, P,0.01 and *, P,0.05 with respect to pSIN co-culture. CCN, cyclin; MCM, minichromosome
maintenance protein; CDK1, cyclin dependent kinase 1. (Bottom panel) Mean fold change of p57
Kip2 mRNA in LEC stimulated by DLL4 or JAG1
compared to pSIN. **, P,0.01 with respect to pSIN co-culture. (D) Expression of cell cycle genes in LEC co-cultured with vGPCR- (left panel) or vFLIP-
expressing cells. Columns are the average of at least two independent experiments. **, P,0.01 and *, P,0.05 with respect to pSIN. (E) mRNA levels
of cell cycle genes suppressed in LEC following KSHV infection. Columns are the average of two independent experiments with respect to LEC.
**, P,0.01 and *, P,0.05.
doi:10.1371/journal.ppat.1000616.g004
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The expression of Notch signaling components has been
reported in KS, but the molecular mechanisms underlying the
activation of this pathway by KSHV have not been established.
Here we show that KSHV manipulates canonical Notch signaling
in LEC by increasing the expression of JAG1 and DLL4 through
vFLIP and vGPCR. The vFLIP-induced increase in JAG1 occurs
through an NFkB-dependent mechanism and mimics the
induction of blood vessel tip cells during pathological angiogenesis
by TNF [8,11]. This provides a new example of the manipulation
of a host endothelial signaling mechanism by KSHV. vGPCR is a
multifunctional protein, but here we show that its induction of
DLL4 is specifically ERK-dependent. How ERK signaling relates
to the Notch pathway in endothelial cells has previously been
unclear and our data indicate a direct link between ERK and
DLL4 expression in LEC. Interestingly, our data also indicate that
the induction of DLL4 in LEC is unlikely to occur as a result of
VEGF stimulation. This is also the first report of a functional
association between KSHV and DLL4.
We show that the increase in levels of the Notch target gene,
HEY1, in KLEC occurs through NOTCH4. Whereas there is an
established functional association between DLL4, NOTCH4 and
NOTCH1 in terms of expression patterns [9,40,49,65], JAG1 has
been shown to be a ligand for multiple Notch receptors, but not
directly for NOTCH4 [66,67]. The induction of HEY1 in
response to vFLIP is dependent on NOTCH4, confirming an
association between JAG1 and NOTCH4 in LEC. We show that
DLL4 can induce expression of an additional Notch target gene,
HES1, though a mechanism dependent on NOTCH1 and
NOTCH4, indicating a specific role for NOTCH1 in LEC.
The outcome of Notch signaling, including signaling strength,
can be influenced by the type of ligand expressed [59]. Using gene
expression profiling, we show that the most significant changes in
gene expression elicited by DLL4 in adjacent cells are more
pronounced compared to the changes elicited in the same genes by
JAG1. HEY1 and HES1 are basic helix-loop-helix transcription
factors that can heterodimerise to enhance Notch signaling effects
[68–70]. The induction of both HES1 and HEY1 by DLL4 could
explain why signaling induced by this ligand is more potent than
JAG1.
Our data also indicate a distinct role for these Notch ligands
during latent (vFLIP) and lytic (vGPCR) infection of LEC by
KSHV. The majority of cells in KS are latently infected with virus,
whereas lytic infection is short-lived and only accounts for a small
percentage of cells [23]. In addition, vGPCR-induced transcripts
are associated with limited temporal expression [71]. The periodic
expression of DLL4 during lytic infection may contribute to
‘‘topping up’’ Notch signaling established by JAG1 during latency.
The increased potency of DLL4-induced signaling may compen-
sate for its potentially restricted expression to permit functional
signaling. The functional outcome of DLL4-stimulated signaling is
dose-dependent [40,65,72,73] and can operate through distinct
spatial expression patterns. [13,58]. While complementary roles
for DLL4 and JAG1 have been suggested during angiogenesis
[58], a mechanism through which expression of these ligands can
be differentially regulated in this context has not been determined.
Our work suggests that KSHV can establish differential upstream
signaling events leading to the expression of DLL4 and JAG1
coincident with lytic and latent infection respectively.
Gene ontology analysis of our expression profiling data did not
indicate significant overall changes in angiogenesis-associated
genes in either DLL4- or JAG1-stimulated cells. However, both
ligands elicited significant suppression of the expression of cell
cycle components in adjacent LEC. A number of these genes
were also suppressed in LEC adjacent to vFLIP- and vGPCR-LEC
and were down regulated in KLEC. Cyclin A1 (CCNA1) expres-
sion was suppressed under all these conditions and has been
indicated as a target of activation of NOTCH1 [74]. Cyclin A1 is
functionally associated with multiple cell cycle components
including CDK1 [75–77], which is also suppressed in our system.
Suppression of cyclin A induces cell cycle arrest in arterial
endothelial cells [78].
The effect of the Notch pathway on the cell cycle has been
associated withquiescenceand reduced proliferationina number of
systems [15–19,61,63,79,80]. In the context of KS, suppression of
cell cycle components could provide a growth advantage to infected
(signal generating) cells over uninfected surrounding cells (Figure 5).
Alternatively, instigation of Notch signaling in adjacent immune
cells could halt them to provide a means of immune escape for the
virus. To fully address the effect of KSHV-induced Notch signaling
on modulation ofthe host immune response to KS would requirean
immunocompetent model of KS, which does not yet exist.
Our data also show that JAG1-induced Notch signaling
increases p57
Kip2 expression in adjacent LEC. Inspection of the
p57
Kip2 promoter reveals two CSL binding sites (data not shown),
making this gene a potentially direct target for JAG1-induced
activation of Notch in LEC. The co-ordinated expression of
p57
Kip2 and HES1 has been associated with quiescence revers-
ibility [14,15]. Our predicted periodic expression of DLL4
provides the potential for co-ordination between p57
Kip2 and
HES1 in KS, suggesting a mechanism by which KSHV may
influence the plasticity of the surrounding cells during lytic
infection, thereby making them more susceptible to reprogram-
ming by the virus [14,15,20,81].
Our co-culture model is representative of the ‘‘tip hypothesis’’ of
branching angiogenesis, whereby the tip cells of developing vessels
express ligand and signal to adjacent cells to adopt the quiescence-
associated stalk phenotype [50,82–84]. The presence of specialised
tip cells has not been described for developing lymphatic vessels
[85], but DLL4 has been implicated in lymphatic sprouting [42].
Our findings indicate a potential role for DLL4 and JAG1 in
sprouting lymphangiogenesis. Furthermore, elucidation of the
Figure 5. Proposed model describing induction of Notch
signaling by KSHV latent (vFLIP) and lytic (vGPCR) infection.
Latent expression of vFLIP and lytic expression of vGPCR induce JAG1
and DLL4 expression in infected cells so that they become Notch signal
generating cells. Interaction between JAG1 and NOTCH4 and DLL4 and
NOTCH4 or NOTCH1 stimulates adjacent, uninfected cells to become
signal receiving cells, in which Notch target genes are upregulated.
doi:10.1371/journal.ppat.1000616.g005
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KSHV in LEC raises the possibility that KS may be susceptible to
treatment with the NOTCH1 Decoy [86], an inhibitor of
NOTCH1 and NOTCH4 signaling, shown to be effective in
neuroblastoma and mouse mammary carcinoma xenografts. Anti-
DLL4 antibodies have been reported to reduce tumour size in
multiple tumour xenograft models [51,87] and could also be
therapeutically relevant in KS treatment. Further studies model-
ling KSHV-induced oncogenesis in the context of KSHV deletion
mutants [88,89] or in the presence of these Notch pathway
inhibitors or would provide insight into this pathway as a possible
target in the management of KS.
Materials and Methods
KSHV production and infection of LEC
LEC were cultured as described and KSHV was produced from
BCBL1 cells and used to infect LEC as previously described
([29,30] and Protocol S1). GFP expression in KLEC was used as
an indicator of KSHV infection; GFP-positive KLEC was typically
approximately 35%, three days post-infection (p.i.).
Lentiviral expression of KSHV genes, DLL4 and JAG1
KSHV genes were cloned from the BC3 and BC1 PEL cell lines
and were expressed using a modified pSIN-MCS lentiviral vector
and produced in 293T cells as previously described [29,30]. DLL4
and JAG1 cDNAs were cloned from HUVEC cDNA into pSIN-
MCS as described in Protocol S1. Lentiviral copies per cell were
determined by qPCR and a maximum of ten copies per cell were
used to avoid cytopathic effects. All experiments shown were
performed three days post-lentiviral infection (p.i.).
Co-culture assays and cell sorting
LEC were infected with the appropriate lentivirus as described
to generate the ligand-expressing (signal generating) cells. LEC to
be designated ‘‘receiving cells’’ were stained with CellTracker
Green CMFDA (Invitrogen) diluted to a final concentration of
5 mM in Optimem (Invitrogen). Receiving cells were mixed with
ligand-expressing donor cells on 10 cm dishes at a ratio of 3:1
[90,91] and co-cultured for 60 hours. Pure populations of signal-
receiving cells were obtained by flow cytometric sorting of the
CellTracker-labelled LEC (MoFlo XDP, Beckman-Coulter) di-
rectly into Qiazol Lysis Reagent (Qiagen). RNA extraction was
performed as described [30].
For GEM experiments, one10 cm dish was used per Affymetrix
chip and 1 mg of total RNA was used to generate cDNA using T7-
linked oligo(dT) primer and the custom SuperScript dscDNA
synthesis kit (Invitrogen). After second-strand synthesis, in vitro
transcription was carried with biotinylated UTP and CTP using
GeneChipH IVT Labeling Kit (http://www.affymetrix.com/
support/technical/technotes/ivt_technote.pdf)
RNA interference
LEC were seeded in 5610
4 cells per well in six-well plates one
day prior to transfection with 100 nM NOTCH1- or NOTCH4-
tagetting or non-targeting siRNA (OnTargetPlus SmartPool,
Dharmacon). Transfections were performed using Oigofectamine
reagent (Invitrogen). Cells were infected with KSHV 48 hours post
siRNA transfection or with the appropriate lentivirus 24 hours
post-transfection.
Pharmacologic inhibitors
The following chemical inhibitors were used: BAY11-7082
(NFkB pathway inhibitor, 5 mM), JNK inhibitor II (25 mM),
SB202190 (p38/MAPK inhibitor, 10 mM), UO126 (MEK inhib-
itor, 10 mM), LY294002 (PI3K inhibitor, 5 mM) and c-secretase
Inhibitor I (GSI-I, Z-Leu-Leu-Nle-CHO (Nle=Norleucine),
5 mM), all from Calbiochem. For LEC and KLEC at 72 hours
p.i., and LEC infected with lentivirus, the inhibitors were added to
the cells for 6 hours, apart from BAY11-7082 and LY294002,
which were added for 2 hours and 4 hours, respectively.
qRT-PCR and qPCR
Extraction of genomic DNA and RNA was performed using
QIAamp DNA mini and RNEasy mini kits (Qiagen) respectively.
DLL4, JAG1, NOTCH4, HEY1 and HES1 mRNA levels were
quantified by qRT-PCR using Taqman Gene Expression Assays
(Applied Biosystems). GAPDH was used as a housekeeping
reference gene and quantified using the SYBR Green Master
Mix (Applied Biosystems) and optimised forward and reverse
primers at a final concentration of 300 nM. Levels of genes
highlighted in the co-culture microarray were quantified in the
same way as GAPDH (primers listed in Table S2). qPCR for
lentiviral copy number was performed as described [30].
Western blotting and immunofluorescence microscopy
Cells were lysed on ice for 30 minutes in buffer (PBS containing
1% NP40 and 0.1% SDS, supplemented with Protease Inhibitor
Cocktail (Sigma)) before clearing by centrifugation. Western
blotting was performed as described [30] using equal amounts of
total protein (20 mg–30 mg) per sample. The following antibodies
were used: goat anti-JAG1 (C-20, 1:500), rabbit anti-NOTCH4
(H225, 1:200) from Santa Cruz Biotechnology; rabbit anti-DLL4,
rabbit anti-cleaved NOTCH1 (both 1:1,000) from Cell Signalling
Technology; mouse anti-GAPDH (6C5, 1:5,000) from Advanced
Immunochemical Inc. Secondary antibodies were from DAKO
and used at a dilution of 1:5,000.
For immunofluorescent assay (IFA), cells were fixed and
permeabilised using formalin 3.7% and PBS-T-0.1% Triton X-
100, and slides were stained as previously described [92]. The anti-
JAG1 antibody was used at 1:50 and anti-goat-FITC (DAKO) was
used at 1:200. Images were taken using an UltraVIEW ERS
confocal microscope (Perkin Elmer).
GEM analysis
Affymetrix hgu133plus2 GEM data was background corrected,
normalised and summarised using the robust multiarray average
(rma) algorithm [93], from the Bioconductor ‘affy’ package for R
[94]. All subsequent analyses and plots show Log2 expression
units. Statistical analyses, p-values and false discovery rates where
shown were calculated using the ‘limma’ package, again from
Bioconductor [95]. Where expression values are shown as a
heatmap the data has been row scaled with standardised
expression values (Z-scores) obtained for each probeset by
subtracting the mean of each row and dividing this by the
standard deviation. KLEC GEM profiles of six pairs of LEC and
KLEC were generated and analyzed as described [29]. KLEC
GEM data are available in the ArrayExpress database with
accession numbers E-MEXP-561. Co-culture GEM data have
been submitted to Gene Expression Omnibus (GEO) and assigned
accession number GSE16547.
Statistics
All experiments were performed in independent replicates and
error bars correspond to standard deviation from the mean.
Statistical significance (P values) was calculated with a two-sided
unpaired Student’s t test. Statistical analysis of the KLEC GEM
KSHV Regulates DLL4 and JAG1 Expression
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false discovery rate correction [29].
Supporting Information
Figure S1 Knock-down of NOTCH (diamond) and NOTCH4
(square) mRNA in KLEC by siRNA targeting NOTCH (N1) or
NOTCH4 (N4). mRNA quantified by qRT-PCR with respect to
expression in KLEC transfected with non-silencing (2) siRNA.
Data points are the average of three independent experiments;
bars are the standard deviation from the mean. Significant knock-
down of NOTCH and NOTCH4 in the presence of the
appropriate siRNA calculated by a two-sided t test with respect
to non-silencing control, **, p,0.01, ***, p,0.001.
Found at: doi:10.1371/journal.ppat.1000616.s001 (0.25 MB TIF)
Figure S2 (A) Relative change in JAG1 mRNA in LEC grown in
LEC-conditioned medium or KLEC-conditioned medium for
48 hours. Columns are the average fold change from three
independent experiments. (B) Expression of NOTCH4 mRNA in
vFLIP-infected LEC transfected with nonsilencing (2) siRNA or
NOTCH4 (N4)-targeting siRNA. Data points are the average of
three independent experiments; bars are the standard deviation
from the mean. mRNA levels measured by qRT-PCR with respect
to vFLIP-LEC transfected with non-silencing siRNA. Significant
knock-down of NOTCH4 calculated by a two-sided t test with
respect to non-silencing control, P=0.014.
Found at: doi:10.1371/journal.ppat.1000616.s002 (0.26 MB TIF)
Figure S3 (A) Relative levels of DLL4 mRNA in LEC infected
with lentivirus expressing vFLIP or pSIN control. Columns are the
average fold change from at least three independent experiments;
bars are the standard deviation. (B) Expression of ERK1 (dark grey
bars) and ERK2 (light grey bars) in LEC and KLEC transfected
with non-silencing (2) or ERK1/2-tagetting (+) siRNA. Columns
are the average fold change from two independent experiments.
Significant knock-down of ERK1/2 is indicated with respect to the
corresponding non-silencing control. *, P,0.05, **, P,0.01. (C)
Relative levels of DLL4 mRNA in LEC infected with lentiviruses
expressing KSHV genes (K15 or Kaposin A) or pSIN control. LEC
infected with a maximum of 10 lentiviral copies per cell. Columns
are the average fold change from at least three independent
experiments. (D) Relative levels of VEGF mRNA in pSIN- and
vGPCR-expressing LEC. Columns are the average fold change
from two independent experiments. **, P,0.01. (E) Relative levels
of DLL4 in LEC cultured in pSIN- or vGPCR-conditioned media
in the presence (+) or absence (2) of a VEGFR inhibitor. Columns
arethe average foldchangefrom twoindependent experimentswith
respect to DMSO-treated pSIN control. (F) DLL4 mRNA levels in
LEC treated with increasing concentrations of VEGF165 at the
indicated time points. Columns are the average fold change from
two independent experiments with respect to untreated LEC
control. (G) JAG1 mRNA levels in LEC infected with pSIN or
vGPCR lentivirus. Columns are the average fold change from three
independent experiments; bars are the standard deviation. Signif-
icance with respect to pSIN. **, P,0.01. (H) mRNA levels of
ORF50 (white bars), ORF26 (light grey bars) and vGPCR (dark
grey bars) in BCBL1 cells infected with pSIN-expressing (2)o r
ORF50-expressing (+) lentivirus. Columns are the average fold
change from three independent experiments. Significance with
respect to pSIN. **, P,0.01, ***, P,0.001. (I) Level of NOTCH4
mRNA in vGPCR-infected LEC transfected with non-silencing (2)
siRNA or NOTCH4 (N4)-targeting siRNA. Data points are the
average of three independent experiments; bars are the standard
deviation from the mean. mRNA levels measured by qRT-PCR
with respect to vGPCR-LEC transfected with nonsilencing siRNA.
Significant knock-down of NOTCH4 with respect to non-silencing
control, P=0.030. (J) (Left panel) Levels of HES1 mRNA in LEC
infected with pSIN- or vGPCRexpressing lentivirus in the presence
of non-silencing (2) siRNA control or siRNA targeting NOTCH
and NOTCH4 (N1/N4). Columns are the average fold change
from three independent experiments. Significance with respect to
non-silencing control *, P,0.05. (Middle panel) Western blot of
NOTCH-ICD in vGPCR-LEC detected using an antibody specific
for NOTCH cleaved at Val1744. (Right panel) Knock-down of
NOTCH (diamond) and NOTCH4 (square) mRNA in vGPCR-
LEC by siRNA targeting NOTCH (N1) or NOTCH4 (N4). mRNA
quantified by qRT-PCR with respect to expression in vGPCR-LEC
transfected with nonsilencing (2) siRNA. Data points are the
average of two independent experiments; bars are the standard
deviation from the mean. Significant knock-down of NOTCH and
NOTCH4 calculated by a two-sided t test with respect to non-
silencing control, *, p,0.05, **, p,0.01.
Found at: doi:10.1371/journal.ppat.1000616.s003 (1.32 MB TIF)
Figure S4 (A) Western blot of protein expression levels of DLL4
and JAG1 in Donor LEC used in the co-culture assay for the
microarray. (B) (Left panel) levels of CD38 (dark grey bars) and
LYVE1 (light grey bars) mRNA in receiving LEC stimulated by
DLL4 or JAG1. (Right panel) levels of NRP1 mRNA in DLL4-
stimulated LEC. Gene expression measured by qRT-PCR relative
to cells cocultured with pSIN-expressing donor LEC. Columns are
the average fold change from three independent co-culture assays;
bars are the standard deviation from the mean. **, p,0.01,*,
p,0.05 with respect to pSIN co-culture. (C) Heat map of the
relative changes in expression of genes most significantly altered in
LEC co-cultured with DLL4 compared to pSIN and the
corresponding changes in cells receiving JAG1-induced signals.
Gene probes are ordered according to the list highlighted in Table
S1. (D) mRNA levels of cyclin F (CCNF), MCM10 and MCM4 in
KLEC. Columns are the average of two independent experiments
with respect to LEC. **, P,0.01 and *, P,0.05.
Found at: doi:10.1371/journal.ppat.1000616.s004 (1.13 MB TIF)
Table S1 List of the most significantly altered genes in LEC
receiving DLL4 or JAG1 signals relative to pSIN. Stringent
selection of genes altered in Receiving LEC using normal p value
adjustment (q,0.05).
Found at: doi:10.1371/journal.ppat.1000616.s005 (0.07 MB XLS)
Table S2 List of the most significantly altered genes in LEC
receiving DLL4 signals relative to pSIN. Gene order corresponds
to the probes illustrated in Figure S4C. Highlights correspond to
genes upregulated (yellow) and down-regulated (pink). M is the
difference in mean expression DLL4-pSIN; the t and P values were
calculated using limma.
Found at: doi:10.1371/journal.ppat.1000616.s006 (0.04 MB XLS)
Table S3 Primer sequences used for qRT-PCR of the indicated
genes and for cloning of DLL4 and JAG1 from HUVEC cDNA
into pSIN. For cloning primers, underlined sequence indicates
junk DNA; bold sequence indicates the restriction site (BamHI for
forward primers, NotI for reverse).
Found at: doi:10.1371/journal.ppat.1000616.s007 (0.02 MB XLS)
Protocol S1 Supporting protocols.
Found at: doi:10.1371/journal.ppat.1000616.s008 (0.02 MB PDF)
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